Generics and biosimilars

This branch covers the medicines that copy or closely follow one already authorised and the documents written for them. Such a medicine is a generic of a chemically synthesised medicine, a hybrid that differs from its reference in form or strength, or a biosimilar of a biological medicine. The branch divides them by the question such a product raises for the writer: which legal route it takes, what a generic is and which documents it needs across its life cycle, what a biosimilar is and how it is developed, how a biosimilar's clinical documents and both products' safety documents differ from an originator's, what interchangeability means for the market a biosimilar enters, and how to explain these products to patients. The statistics of biosimilar equivalence trials are left to clinical trial design, the waiver of an in vivo bioequivalence study to biowaivers, the safety documents of any medicine to pharmacovigilance, and lay summaries in general to the documents for trial participants.

• Choosing the regulatory pathway for a generic, hybrid or biosimilar — why the route is settled first, the European legal bases from the full application to the informed-consent duplicate, the US application types, follow-on biologics and the 351(k) biosimilar application, patent information and exclusivity, and planning when more than one route is open
• What a generic medicine is — how a generic follows a new drug, what it shares with its reference and how its inactive ingredients may differ, why it is a small molecule, approval on equivalence, who makes it and why it costs less, and when it may be marketed, including India's compulsory licences
• Documents across a generic medicine's life cycle — the documents written at each stage, the bioequivalence study, dissolution testing, the abridged dossier module by module, and the periodic safety update reports and renewal addendum that follow approval
• What a biosimilar is and how one is developed — why a biological copy can only be similar, how regulators define and name it, the reference product, the development that puts analytics first and keeps the clinical programme lean, immunogenicity and extrapolation, the range of biosimilars, and the regulatory questions still open
• Writing biosimilar clinical study reports and submission documents — the similarity mindset in results, the report sections a biosimilar adds to, Module 2 for a programme of two studies, where immunogenicity, extrapolation and other special topics are placed, alignment with the quality dossier, and the writer's role
• Pharmacovigilance documents for generics and biosimilars — the lean approach to the safety concerns, the development report's own reporting cycle, the risk management plan aligned with the originator's, and the periodic report that follows the originator's data lock points
• Interchangeability, switching and the biosimilar market — the three terms and how the EU and the US decide them, why the market exists and how far it has grown, market access, how originators and new competitors respond, the European experience, and biosimilar insulins
• Explaining generics and biosimilars to lay readers — why patients need lay materials on these medicines, when a lay summary is required, and plain-language wording for the terms they bring